Avinger (NASDAQ:AVGR) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Avinger (NASDAQ:AVGR) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the medical device company’s stock.

Separately, HC Wainwright restated a buy rating and issued a $5.00 price objective on shares of Avinger in a research note on Thursday, March 21st.

Avinger Stock Performance

NASDAQ:AVGR opened at $3.73 on Wednesday. The stock’s 50-day simple moving average is $3.47 and its 200 day simple moving average is $3.34. The company has a market cap of $5.93 million, a P/E ratio of -0.14 and a beta of 1.26. Avinger has a 52-week low of $2.50 and a 52-week high of $18.00.

Avinger (NASDAQ:AVGR) last released its earnings results on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.64 by ($4.57). The company had revenue of $1.91 million during the quarter, compared to analyst estimates of $2.52 million. As a group, equities analysts predict that Avinger will post -2.08 earnings per share for the current fiscal year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.